The purpose of this research study is to evaluate tau distribution in the brain of subjects
with: ALS caused by different genetic mutations, any mutation carriers (with or without
symptoms), any non-mutation carrier, any sporadic FTD, normal controls.
1. Male or female participants, at least 18 years of age.
2. Clinically diagnosed with amyotrophic lateral sclerosis (ALS), fronto-temporal
dementia (FTD), or both; or a carrier of a mutation known to cause ALS or FTD (with
or without symptoms); or a normal control.
3. Participant is able and willing to undergo testing (psychometric testing, MRI or CT,
PET, radioactive tracer injection; for those unable to undergo an MRI, CT will be
used to generate regions-of-interest).
4. Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug
1. Has any condition that, in the Investigator's opinion, could increase risk to the
participant, limit the participant's ability to tolerate the experimental procedures,
or interfere with the collection/analysis of the data (for example, participants with
significant respiratory involvement may not be able to lie flat during the scanning
2. Is deemed likely unable to perform the imaging procedures for any reason.
3. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT
4. Has hypersensitivity to F 18 T807 or any of its excipients.
5. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to
lie still for long periods) that make it unsafe for the individual to participate.
6. Severe claustrophobia.
7. Currently pregnant or breast-feeding.
Tammie Benzinger, MD, PhD
Washington University School of Medicine
Kelley Jackson, BA
Phone: 314 362 6737